We use cookies to improve our service and to tailor our content and advertising to you. More infoClose You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policyClose
Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on thebmj.com. Although a selection of rapid responses will be included online and in print as readers' letters, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window. Letters are indexed in PubMed.
The National Collaborating Centre for Mental Health and NICE would
like to point out that one of the recommendations summarised in BMJ 2011;
2011; 342:c7460 was reworded before publication of the guideline but after
acceptance of the BMJ manuscript. The recommendation in the guideline now
reads:
"If a person with GAD chooses drug treatment, offer a selective
serotonin reuptake inhibitor (SSRI). Consider offering sertraline first
because it is the most cost-effective drug, but note that at the time of
publication (January 2011) sertraline did not have UK marketing
authorisation for this indication. Informed consent should be obtained
and documented. Monitor the person carefully for adverse reactions."
Amending a recommendation on sertraline for use in GAD
The National Collaborating Centre for Mental Health and NICE would
like to point out that one of the recommendations summarised in BMJ 2011;
2011; 342:c7460 was reworded before publication of the guideline but after
acceptance of the BMJ manuscript. The recommendation in the guideline now
reads:
"If a person with GAD chooses drug treatment, offer a selective
serotonin reuptake inhibitor (SSRI). Consider offering sertraline first
because it is the most cost-effective drug, but note that at the time of
publication (January 2011) sertraline did not have UK marketing
authorisation for this indication. Informed consent should be obtained
and documented. Monitor the person carefully for adverse reactions."
Competing interests: No competing interests